To honor the memory of Broadway actor and singer Rebecca Luker, who died of complications due to amyotrophic lateral sclerosis (ALS) last year, Target ALS will present a live-streamed concert on May 4. All proceeds will go to support ALS research, the nonprofit group announced. The show, called “Becca,”…
News
Editor’s note: The ALS News Today team is providing in-depth coverage of the 2021 MDA Virtual Clinical and Scientific Conference, March 15–18. Go here to read the latest stories from the conference. Early treatment with Radicava (edaravone) significantly lowers the cumulative risk of death, need for mechanical and permanent ventilation,…
Editor’s note: The ALS News Today team is providing in-depth coverage of the 2021 MDA Virtual Clinical and Scientific Conference, March 15–18. Go here to read the latest stories from the conference. Long-term treatment with AMX0035 significantly lowers the risk of death, and the need for permanent ventilation and hospitalization…
Editor’s note: The ALS News Today team is providing in-depth coverage of the 2021 MDA Virtual Clinical and Scientific Conference, March 15–18. Go here to read the latest stories from the conference. WVE-004, an investigational treatment for people with amyotrophic lateral sclerosis…
Editor’s note: The ALS News Today team is providing in-depth coverage of the 2021 MDA Virtual Clinical and Scientific Conference, March 15–18. Go here to read the latest stories from the conference. Amyotrophic lateral sclerosis (ALS) patients living in the Midwest — the U.S. region with the highest ALS frequency —…
Editor’s note: The ALS News Today team is providing in-depth coverage of the 2021 MDA Virtual Clinical and Scientific Conference, March 15–18. Go here to read the latest stories from the conference. Respiratory symptoms in people with amyotrophic lateral sclerosis (ALS) significantly affect their ability to independently perform daily tasks,…
The first patient has been enrolled in a Phase 2a clinical trial investigating Helixmith’s gene therapy Engensis (VM202) for the treatment of amyotrophic lateral sclerosis (ALS), the company announced. The REViVALS-1A study (NCT04632225) intends to recruit 18 patients across four clinical sites in the U.S. Enrollment is open…
Editor’s note: The ALS News Today team is providing in-depth coverage of the 2021 MDA Virtual Clinical and Scientific Conference, March 15–18. Go here to read the latest stories from the conference. Variants in the WWOX gene may contribute to the development of amyotrophic lateral sclerosis (ALS)…
The HEALEY ALS platform trial, which is evaluating the safety and efficacy of several potential treatments for amyotrophic lateral sclerosis (ALS), has passed the 50% participant enrollment target for its first three regimens. The investigational treatments are UCB’s zilucoplan, Biohaven Pharmaceuticals’ verdiperstat, and Clene Nanomedicine’s CNM-Au8. A fourth candidate…
Mitsubishi Tanabe Pharma Corporation (MTPC) is opening a new research site in the Boston area dedicated to discovering new therapeutic targets in amyotrophic lateral sclerosis (ALS) and other diseases of the central nervous system. Located in the SmartLabs biotechnology hub in Cambridge, Massachusetts, the company’s NeuroDiscovery Lab is scheduled…
Recent Posts
- Revamped plan aims to hasten US approval of treatment for ALS
- Landing the ‘Brick’ lets us look back on the great mattress mishap with a laugh
- Trial tests fever-inducing device as potential treatment for ALS
- FDA puts experimental T-cell treatment for ALS on fast track
- Guest Voice: What it means to be an ALS caregiver